CannPal Granted SME Status by the European Medicines Agency (EMA)

Key Highlights CannPal has received confirmation of SME (Small and Medium size Enterprises) status,with the European Medicines Agency (EMA)  The European Medicines Agency is the European Union agency responsible for the evaluation and regulation of veterinary medicinal products (VMP’s) in Europe; The SME status allows CannPal a line of communication with the EMA for the … Continue reading

December 18, 2017 Latest News, News

CannPal Granted Import Licence by the Office of Drug Control

Key Highlights CannPal has been granted a licence to import medical cannabis by the Australian Government Department of Health’s Office of Drug Control (ODC) CannPal can now apply to import its cannabis formulations for clinical trials commencing Q1 CY18 CannPal received a licence to possess and supply prohibited substances by the NSW State Department of … Continue reading

November 22, 2017 Latest News, News

How does the Endocannabinoid System Work?

Have you ever wondered how Cannabis works? It works by replicating a process that happens in the body naturally. The major compounds in cannabis are called Cannabinoids, with the two most common being CBD and THC. These compounds are able to tap into a network in our bodies called the endocannabinoid system. This occurs for … Continue reading

November 14, 2017 Latest News, News, Uncategorized

CannPal Appoints Head of Clinical Development and R&D

Key Highlights CannPal adds to its management team by appointing animal health industry executive Dr Margaret Curtis as Head of Clinical Development and R&D Dr Curtis is a qualified veterinarian with 17 years’ of senior executive experience at global market leading animal health Company, Elanco (Eli Lilly) She will be responsible for managing the clinical … Continue reading

November 10, 2017 Latest News, News

CannPal Granted a Permit to Possess and Supply Cannabis by NSW State Department of Health

Key Highlights CannPal has been granted a permit to possess and supply tetrahydrocannabinol and cannabidiol for the purpose of scientific research by the NSW State Department of Health The permit allows the provision of cannabis to researchers in NSW for the purpose of CannPal’s clinical trials in Q1 CY18 The authorisation has been issued under … Continue reading

November 3, 2017 Latest News, News, Uncategorized

CannPal Advances Research Through Agreement with The University of Queensland

Key Highlights CannPal has entered into a research services agreement with The University of Queensland The University of Queenlands’s TetraQ Research Infrastructure Centre will provide bio-analytical services for CannPal’s pharmacokinetic and safety studies TetraQ will develop and validate a method for quantification of cannabidiol and tetrahydrocannabinol concentration in dog plasma samples Over 48 dogs will … Continue reading

October 31, 2017 Latest News, News

CannPal Receives Ethics Approval for the Commencement of Clinical Trial in Dogs

Key Highlights Ethics approval received for large pharmacokinetic and safety study in dogs CannPal’s lead drug candidate, CPAT-01, is being developed as a pain medication for companion animals The trial subjects will be evaluated for safety, tolerability and clinical observations using both psychoactive (THC) and non-psychoactive (CBD) cannabis compounds Over 48 dogs will be evaluated … Continue reading

October 25, 2017 Latest News, News

CannPal prepares for ASX listing in mission to ease pet pain with medical cannabis

Pet owners may soon be one step closer to accessing medical cannabis as a reliever for pet pain thanks to CannPal, a Sydney-based pharmatech startup that is looking to raise $6 million when it lists on the Australian Securities Exchange later this year. CannPal wants to develop cannabis-based products to aid veterinarians in administering in … Continue reading

September 29, 2017 Latest News, News

CannPal Lodges Prospectus for ASX Listing

Medical Cannabis Animal Health Company CannPal Launches Prospectus A leader in cannabinoid derived animal therapeutics Prospectus launch to raise $6 million and list on ASX Australian roadshow to commence September 5 2017 Animal health company CannPal Animal Therapeutics Limited (CannPal or the Company, proposed ticker code, ASX:CP1) is pleased to announce the successful lodgement of … Continue reading

August 28, 2017 Latest News